Silicon Canals
No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • AI and chatbots
    • FinTech
    • Business Wire
    • Travel & Mobility
    • Coin Canals
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Amsterdam
    • Community partners
    • Remote: Tech Talent Report
    • Guest Contributions
  • Find a job
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Sign up for our newsletter!
    • Contribute your content
    • Team
    • About us
  • Partner with us
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • AI and chatbots
    • FinTech
    • Business Wire
    • Travel & Mobility
    • Coin Canals
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Amsterdam
    • Community partners
    • Remote: Tech Talent Report
    • Guest Contributions
  • Find a job
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Sign up for our newsletter!
    • Contribute your content
    • Team
    • About us
  • Partner with us
No Result
View All Result
Silicon Canals
No Result
View All Result

Sweden’s biotech and medtech company SmartCella raises €32M; plans to go public in 2-3 years

Vishal Singh by Vishal Singh
September 30, 2021
in (Crowd)funding, Health & Medtech, News
SmartCella

Staffan Holmin, MD, Ph.D., CEO of SmartCella | Image credit: Karolinska Univ.sjuk (Twitter)

LinkedInTwitterWhatsAppFacebook
Read this article in:

Stockholm-based SmartCella Holding AB, a biotechnology and medtech company that wants to develop therapeutic treatments for patients who have exhausted all other options, announced that it has raised SEK 328M (approx €32M) to further advance and accelerate the development of core technologies in its three business units – Procella Therapeutics, Smartwise, and SvedMed Solutions.

The round was led by advisor SEB, along with a group of investors including AMF, SEB Pension, Alto Cumulus, and Celox. Existing investors AP4 and the founders Prof. Kenneth Chien, Thomas von Koch, and Christian Kinch also participated in this round.

Speaking on the development, CEO of SmartCella, Staffan Holmin says, “We are very pleased to have such a well-renowned group of institutional and private investors joining us as we now accelerate the development of Procella, Smartwise, and SvedMed Solutions towards first-in-human studies, as well as to establish GMP manufacturing capabilities.”

“The financing will enable the company to move to the next phase and will take us to an IPO in 2-3 years,” adds Christian Kinch, Chairman & co-founder of SmartCella.

About Procella Therapeutics

Procella Therapeutics was started in 2018 to create the next generation of cell-based therapies for patients who are running out of options. It focuses on stem cell treatments for patients with advanced heart failure.

For patients who have suffered a heart attack, a large number of heart cells die, which causes heart failure and significant morbidity and mortality. With cardiac progenitor cells, Procella Therapeutics, together with AstraZeneca, is developing a new way to regenerate those parts of the heart that have been damaged by a heart attack.

In animal tests, the company’s technology has shown that unique and novel heart progenitor cells have the capability of creating new muscle in hearts damaged from a heart attack. The company is now gearing for the first human studies.

The stem cell technology was developed at the Karolinska Institutet by Kenneth Chien, Distinguished Professor of the Swedish Research Council and Director of the Wallenberg-Karolinska Cardiovascular Initiative.

What does Smartwise offer?

In 1953, Sven-Ivar Seldinger developed a technique for inserting catheters into the blood vessels via an INtroducer – this method is used in all hospitals throughout the world.

Using this as inspiration, Smartwise was founded in 2015 to develop the Extroducer technology invented in the laboratory of Staffan Holmin (MD, Ph.D., CEO of SmartCella). Holmin’s team developed the EXtroducer infusion catheter, a novel catheter that uses the same Seldinger principle to exit blood vessels and reach adjacent tissues. Large animal proof of principle studies at the Karolinska Institutet in tissues, such as heart, kidney, pancreas, and liver, have been performed.

The EXtroducer can be integrated with many off-the-shelf micro-catheters and navigated into the microvasculature. A microvasculature is the system of tiny blood vessels, including capillaries, venules, and arterioles, that perfuse the body’s tissues.

SvedMed Solutions

The third business unit, SvedMed Solutions, works on developing novel methods for RNA-based therapies and methods for administration and the delivery of such therapies.

Kenneth Chien, co-founder and the main shareholder of SmartCella and also a co-founder of Moderna says, “The Stockholm region has all necessary components, including a strong IT-sector, to become a world-leading biotech cluster.”

Tags: fundingHealth-& Medtechmedtechnews
ShareTweetSendShare

Partner content | Partner with us

Germany’s Sastrify expands market reach; acquires Amsterdam-based Pengu and raises fresh funds

Amsterdam-based startups that are fundraising right now

Founders on Bootstrapping: Insight’s Farzan Najmeddin on when to bootstrap, future of work, and funding

Check out the Amsterdam startups that raised funding in November; 5 of them are hiring

Dutch-Swiss startup Cradle raises €21.9M for pioneering Generative AI in protein design

Silicon Canals | Find a job

Top news | from Amsterdam

Amsterdam’s LAYCO raises €300K to make healthcare more sustainable and accessible

Amsterdam’s ImpactPilot set to revolutionise customer success through HubSpot integration

Meet the winners of the Amsterdam Science & Innovation Award 2023

Amsterdam’s grocery app Crisp bags €35M from Adriaan Mol, Thomas Plantenga, others 

Amsterdam fintech Silverflow raises €15M to fuel its “aggressive” global expansion plans

  • About Silicon Canals
  • Partner with Silicon Canals
  • Impressum
  • Contact us
  • Sign up for our newsletter!
  • Find a job
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

No Result
View All Result
  • Home
  • News
    • News
    • Startups
    • Scaleups
    • AI and chatbots
    • FinTech
    • Business Wire
    • Travel & Mobility
    • Coin Canals
    • Software & SaaS
    • Event News
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Exclusive content
    • Partner content
    • Amsterdam
    • Community partners
    • Remote: Tech Talent Report
    • Guest Contributions
  • Find a job
  • Tech Events
    • Technology Events
    • Event News
    • Submit event
  • Contact
    • Contact us
    • Sign up for our newsletter!
    • Contribute your content
    • Team
    • About us
  • Partner with us

Silicon Canals © 2014-2023 | Design: Bright Idiots. Images: Depositphotos

X
X